Pub Date : 2017-01-01DOI: 10.1016/j.rbre.2017.06.003
Alexandre Wagner Silva de Souza , Ana Luisa Calich , Henrique de Ataíde Mariz , Manuella Lima Gomes Ochtrop , Ana Beatriz Santos Bacchiega , Gilda Aparecida Ferreira , Jozelia Rêgo , Mariana Ortega Perez , Rosa Maria Rodrigues Pereira , Wanderley Marques Bernardo , Roger Abramino Levy
The purpose of these recommendations is to guide the appropriate induction treatment of antineutrophil cytoplasmic antibody-associated vasculitis (AAV) patients with active disease. The recommendations proposed by the Vasculopathies Committee of the Brazilian Society Rheumatology for induction therapy of AAV, including granulomatosis with polyangiitis, microscopic polyangiitis and renal-limited vasculitis, were based on systematic literature review and expert opinion. Literature review was performed using Medline (PubMed), EMBASE and Cochrane database to retrieve articles until October 2016. PRISMA guidelines were used for the systematic review and articles were assessed according to the Oxford levels of evidence. Sixteen recommendations were made regarding different aspects of induction therapy for AAV. The purpose of these recommendations is to serve as a guide for therapeutic decisions by health care professionals in the management of AAV patients presenting active disease.
{"title":"Recommendations of the Brazilian Society of Rheumatology for the induction therapy of ANCA-associated vasculitis","authors":"Alexandre Wagner Silva de Souza , Ana Luisa Calich , Henrique de Ataíde Mariz , Manuella Lima Gomes Ochtrop , Ana Beatriz Santos Bacchiega , Gilda Aparecida Ferreira , Jozelia Rêgo , Mariana Ortega Perez , Rosa Maria Rodrigues Pereira , Wanderley Marques Bernardo , Roger Abramino Levy","doi":"10.1016/j.rbre.2017.06.003","DOIUrl":"10.1016/j.rbre.2017.06.003","url":null,"abstract":"<div><p>The purpose of these recommendations is to guide the appropriate induction treatment of antineutrophil cytoplasmic antibody-associated vasculitis (AAV) patients with active disease. The recommendations proposed by the Vasculopathies Committee of the Brazilian Society Rheumatology for induction therapy of AAV, including granulomatosis with polyangiitis, microscopic polyangiitis and renal-limited vasculitis, were based on systematic literature review and expert opinion. Literature review was performed using Medline (PubMed), EMBASE and Cochrane database to retrieve articles until October 2016. PRISMA guidelines were used for the systematic review and articles were assessed according to the Oxford levels of evidence. Sixteen recommendations were made regarding different aspects of induction therapy for AAV. The purpose of these recommendations is to serve as a guide for therapeutic decisions by health care professionals in the management of AAV patients presenting active disease.</p></div>","PeriodicalId":101096,"journal":{"name":"Revista Brasileira de Reumatologia (English Edition)","volume":"57 ","pages":"Pages 484-496"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.rbre.2017.06.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35272134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-01-01DOI: 10.1016/j.rbre.2016.07.016
Benito Lourenço , Katia T. Kozu , Gabriela N. Leal , Marco F. Silva , Elisabeth G.C. Fernandes , Camila M.P. França , Fernando H.C. Souza , Clovis A. Silva
Contraception is an important issue and should be a matter of concern in every medical visit of adolescent and young patients with chronic rheumatic diseases. This narrative review discusses contraception methods in adolescents with juvenile systemic lupus erythematosus (JSLE), antiphospholipid syndrome (APS), juvenile idiopathic arthritis (JIA) and juvenile dermatomyositis (JDM). Barrier methods are safe and their use should be encouraged for all adolescents with chronic rheumatic diseases. Combined oral contraceptives (COC) are strictly prohibited for JSLE and APS patients with positive antiphospholipid antibodies. Reversible long-acting contraception can be encouraged and offered routinely to the JSLE adolescent patient and other rheumatic diseases. Progestin-only pills are safe in the majority of rheumatic diseases, although the main concern related to its use by adolescents is poor adherence due to menstrual irregularity. Depot medroxyprogesterone acetate injections every three months is a highly effective contraception strategy, although its long-term use is associated with decreased bone mineral density. COC or other combined hormonal contraceptive may be options for JIA and JDM patients. Oral levonorgestrel should be considered as an emergency contraception method for all adolescents with chronic rheumatic diseases, including patients with contraindication to COC.
{"title":"Contraception for adolescents with chronic rheumatic diseases","authors":"Benito Lourenço , Katia T. Kozu , Gabriela N. Leal , Marco F. Silva , Elisabeth G.C. Fernandes , Camila M.P. França , Fernando H.C. Souza , Clovis A. Silva","doi":"10.1016/j.rbre.2016.07.016","DOIUrl":"10.1016/j.rbre.2016.07.016","url":null,"abstract":"<div><p>Contraception is an important issue and should be a matter of concern in every medical visit of adolescent and young patients with chronic rheumatic diseases. This narrative review discusses contraception methods in adolescents with juvenile systemic lupus erythematosus (JSLE), antiphospholipid syndrome (APS), juvenile idiopathic arthritis (JIA) and juvenile dermatomyositis (JDM). Barrier methods are safe and their use should be encouraged for all adolescents with chronic rheumatic diseases. Combined oral contraceptives (COC) are strictly prohibited for JSLE and APS patients with positive antiphospholipid antibodies. Reversible long-acting contraception can be encouraged and offered routinely to the JSLE adolescent patient and other rheumatic diseases. Progestin-only pills are safe in the majority of rheumatic diseases, although the main concern related to its use by adolescents is poor adherence due to menstrual irregularity. Depot medroxyprogesterone acetate injections every three months is a highly effective contraception strategy, although its long-term use is associated with decreased bone mineral density. COC or other combined hormonal contraceptive may be options for JIA and JDM patients. Oral levonorgestrel should be considered as an emergency contraception method for all adolescents with chronic rheumatic diseases, including patients with contraindication to COC.</p></div>","PeriodicalId":101096,"journal":{"name":"Revista Brasileira de Reumatologia (English Edition)","volume":"57 1","pages":"Pages 73-81"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.rbre.2016.07.016","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"55048611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-01-01DOI: 10.1016/j.rbre.2017.05.006
Claudia Diniz Lopes Marques , Angela Luzia Branco Pinto Duarte , Aline Ranzolin , Andrea Tavares Dantas , Nara Gualberto Cavalcanti , Rafaela Silva Guimarães Gonçalves , Laurindo Ferreira da Rocha Junior , Lilian David de Azevedo Valadares , Ana Karla Guedes de Melo , Eutilia Andrade Medeiros Freire , Roberto Teixeira , Francisco Alves Bezerra Neto , Marta Maria das Chagas Medeiros , Jozélio Freire de Carvalho , Mario Sergio F. Santos , Regina Adalva de L. Couto Océa , Roger A. Levy , Carlos Augusto Ferreira de Andrade , Geraldo da Rocha Castelar Pinheiro , Mirhelen Mendes Abreu , Georges Christopoulos
Chikungunya fever has become a relevant public health problem in countries where epidemics occur. Until 2013, only imported cases occurred in the Americas, but in October of that year, the first cases were reported in Saint Marin island in the Caribbean. The first autochthonous cases were confirmed in Brazil in September 2014; until epidemiological week 37 of 2016, 236,287 probable cases of infection with Chikungunya virus had been registered, 116,523 of which had serological confirmation. Environmental changes caused by humans, disorderly urban growth and an ever-increasing number of international travelers were described as the factors responsible for the emergence of large-scale epidemics. Clinically characterized by fever and joint pain in the acute stage, approximately half of patients progress to the chronic stage (beyond 3 months), which is accompanied by persistent and disabling pain. The aim of the present study was to formulate recommendations for the diagnosis and treatment of Chikungunya fever in Brazil. A literature review was performed in the MEDLINE, SciELO and PubMed databases to ground the decisions for recommendations. The degree of concordance among experts was established through the Delphi method, involving 2 in-person meetings and several online voting rounds. In total, 25 recommendations were formulated and divided into 3 thematic groups: (1) clinical, laboratory and imaging diagnosis; (2) special situations; and (3) treatment. The first 2 themes are presented in part 1, and treatment is presented in part 2.
{"title":"Recommendations of the Brazilian Society of Rheumatology for diagnosis and treatment of Chikungunya fever. Part 1 – Diagnosis and special situations","authors":"Claudia Diniz Lopes Marques , Angela Luzia Branco Pinto Duarte , Aline Ranzolin , Andrea Tavares Dantas , Nara Gualberto Cavalcanti , Rafaela Silva Guimarães Gonçalves , Laurindo Ferreira da Rocha Junior , Lilian David de Azevedo Valadares , Ana Karla Guedes de Melo , Eutilia Andrade Medeiros Freire , Roberto Teixeira , Francisco Alves Bezerra Neto , Marta Maria das Chagas Medeiros , Jozélio Freire de Carvalho , Mario Sergio F. Santos , Regina Adalva de L. Couto Océa , Roger A. Levy , Carlos Augusto Ferreira de Andrade , Geraldo da Rocha Castelar Pinheiro , Mirhelen Mendes Abreu , Georges Christopoulos","doi":"10.1016/j.rbre.2017.05.006","DOIUrl":"10.1016/j.rbre.2017.05.006","url":null,"abstract":"<div><p>Chikungunya fever has become a relevant public health problem in countries where epidemics occur. Until 2013, only imported cases occurred in the Americas, but in October of that year, the first cases were reported in Saint Marin island in the Caribbean. The first autochthonous cases were confirmed in Brazil in September 2014; until epidemiological week 37 of 2016, 236,287 probable cases of infection with Chikungunya virus had been registered, 116,523 of which had serological confirmation. Environmental changes caused by humans, disorderly urban growth and an ever-increasing number of international travelers were described as the factors responsible for the emergence of large-scale epidemics. Clinically characterized by fever and joint pain in the acute stage, approximately half of patients progress to the chronic stage (beyond 3 months), which is accompanied by persistent and disabling pain. The aim of the present study was to formulate recommendations for the diagnosis and treatment of Chikungunya fever in Brazil. A literature review was performed in the MEDLINE, SciELO and PubMed databases to ground the decisions for recommendations. The degree of concordance among experts was established through the Delphi method, involving 2 in-person meetings and several online voting rounds. In total, 25 recommendations were formulated and divided into 3 thematic groups: (1) clinical, laboratory and imaging diagnosis; (2) special situations; and (3) treatment. The first 2 themes are presented in part 1, and treatment is presented in part 2.</p></div>","PeriodicalId":101096,"journal":{"name":"Revista Brasileira de Reumatologia (English Edition)","volume":"57 ","pages":"Pages 421-437"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.rbre.2017.05.006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35205770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-01-01DOI: 10.1016/j.rbre.2014.12.006
Yesim Garip , Filiz Eser , Hatice Bodur , Bedriye Baskan , Filiz Sivas , Ozlem Yilmaz
Objective
To determine the impact of postpolio-syndrome on quality of life in polio survivors.
Methods
Forty polio survivors were included in the study. Twenty-one patients fulfilling the Halstead's postpolio-syndrome criteria participated in postpolio-syndrome group. The remaining nineteen patients formed non-postpolio-syndrome group. Control group was composed of forty healthy subjects. Quality of life was evaluated by Nottingham Health Profile, depression by Beck Depression Scale and fatigue by Fatigue Symptom Inventory. Isometric muscle strength was measured by manual muscle testing.
Results
Total manual muscle testing score was 26.19 ± 13.24 (median: 29) in postpolio-syndrome group and 30.08 ± 8.9 (median: 32) in non-postpolio-syndrome group. Total manual muscle testing scores of non-postpolio-syndrome group were significantly higher than that of postpolio-syndrome group. Patients with postpolio-syndrome reported significantly higher levels of fatigue and reduced quality of life in terms of physical mobility, pain and energy when compared with patients without postpolio-syndrome and control group. It was not reported a statistically significant difference in social and emotional functioning and sleep quality between postpolio-syndrome, non-postpolio-syndrome and control groups. Also it was not found any statistically significant difference in Beck Depression Scale scores among the groups.
Conclusions
Postpolio-syndrome has a negative impact on quality of life in terms of functional status, severity of pain and energy. The identification, early recognition and rehabilitation of postpolio-syndrome patients may result in an improvement in their quality of life.
{"title":"Health related quality of life in Turkish polio survivors: impact of post-polio on the health related quality of life in terms of functional status, severity of pain, fatigue, and social, and emotional functioning","authors":"Yesim Garip , Filiz Eser , Hatice Bodur , Bedriye Baskan , Filiz Sivas , Ozlem Yilmaz","doi":"10.1016/j.rbre.2014.12.006","DOIUrl":"10.1016/j.rbre.2014.12.006","url":null,"abstract":"<div><h3>Objective</h3><p>To determine the impact of postpolio-syndrome on quality of life in polio survivors.</p></div><div><h3>Methods</h3><p>Forty polio survivors were included in the study. Twenty-one patients fulfilling the Halstead's postpolio-syndrome criteria participated in postpolio-syndrome group. The remaining nineteen patients formed non-postpolio-syndrome group. Control group was composed of forty healthy subjects. Quality of life was evaluated by Nottingham Health Profile, depression by Beck Depression Scale and fatigue by Fatigue Symptom Inventory. Isometric muscle strength was measured by manual muscle testing.</p></div><div><h3>Results</h3><p>Total manual muscle testing score was 26.19<!--> <!-->±<!--> <!-->13.24 (median: 29) in postpolio-syndrome group and 30.08<!--> <!-->±<!--> <!-->8.9 (median: 32) in non-postpolio-syndrome group. Total manual muscle testing scores of non-postpolio-syndrome group were significantly higher than that of postpolio-syndrome group. Patients with postpolio-syndrome reported significantly higher levels of fatigue and reduced quality of life in terms of physical mobility, pain and energy when compared with patients without postpolio-syndrome and control group. It was not reported a statistically significant difference in social and emotional functioning and sleep quality between postpolio-syndrome, non-postpolio-syndrome and control groups. Also it was not found any statistically significant difference in Beck Depression Scale scores among the groups.</p></div><div><h3>Conclusions</h3><p>Postpolio-syndrome has a negative impact on quality of life in terms of functional status, severity of pain and energy. The identification, early recognition and rehabilitation of postpolio-syndrome patients may result in an improvement in their quality of life.</p></div>","PeriodicalId":101096,"journal":{"name":"Revista Brasileira de Reumatologia (English Edition)","volume":"57 1","pages":"Pages 1-7"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.rbre.2014.12.006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"55048067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-01-01DOI: 10.1016/j.rbre.2017.05.005
Claudia Leiko Yonekura , Rene Donizeti Ribeiro Oliveira , David C. Titton , Roberto Ranza , Aline Ranzolin , André L. Hayata , Ângela Duarte , Inês G. Silveira , Hellen M. da S. de Carvalho , Júlio C. Bertacini de Moraes , Mirhelen Mendes de Abreu , Valéria Valim , Washington Bianchi , Claiton Viegas Brenol , Ivanio A. Pereira , Izaias Costa , José C. Macieira , José R.S. Miranda , Luiz S. Guedes-Barbosa , Manoel B. Bertolo , Paulo Louzada-Junior
Objectives
To assess the incidence of tuberculosis and to screen for latent tuberculosis infection among Brazilians with rheumatoid arthritis using biologics in clinical practice.
Patients and methods
This cohort study used data from the Brazilian Registry of Biological Therapies in Rheumatic Diseases (Registro Brasileiro de Monitoração de Terapias Biológicas – BiobadaBrasil), from 01/2009 to 05/2013, encompassing 1552 treatments, including 415 with only synthetic disease-modifying anti-rheumatic drugs, 942 synthetic DMARDs combined with anti-tumor necrosis factor (etanercept, infliximab, adalimumab) and 195 synthetic DMARDs combined with other biologics (abatacept, rituximab and tocilizumab). The occurrence of tuberculosis and the drug exposure time were assessed, and screening for tuberculosis was performed. Statistical analysis: Unpaired t-test and Fisher's two-tailed test; p < 0.05.
Results
The exposure times were 981 patient-years in the controls, 1744 patient-years in the anti-TNF group (adalimumab = 676, infliximab = 547 and etanercept = 521 patient-years) and 336 patient-years in the other biologics group. The incidence rates of tuberculosis were 1.01/1000 patient-years in the controls and 2.87 patient-years among anti-TNF users (adalimumab = 4.43/1000 patient-years; etanercept = 1.92/1000 patient-years and infliximab = 1.82/1000 patient-years). No cases of tuberculosis occurred in the other biologics group. The mean drug exposure time until the occurrence of tuberculosis was 27(11) months for the anti-TNF group.
Conclusions
The incidence of tuberculosis was higher among users of synthetic DMARDs and anti-TNF than among users of synthetic DMARDs and synthetic DMARDs and non-anti-TNF biologics and also occurred later, suggesting infection during treatment and no screening failure.
目的评估巴西类风湿关节炎患者的结核病发病率,并在临床应用生物制剂筛查潜伏性结核病感染。患者和方法该队列研究使用了2009年1月至2013年5月巴西风湿病生物疗法登记处(Registro Brasileiro de monitora o de Terapias Biológicas - BiobadaBrasil)的数据,包括1552种治疗方法,其中415种仅使用合成疾病改善抗风湿药,942种合成dmard联合抗肿瘤坏死因子(依那西普,英夫利昔单抗,阿达木单抗)和195种合成dmard联合其他生物制剂(阿巴接受普,利妥昔单抗和托珠单抗)。评估结核的发生情况和药物暴露时间,并进行结核筛查。统计分析:非配对t检验和Fisher双尾检验;p & lt;0.05.结果对照组暴露时间为981例患者-年,抗tnf组暴露时间为1744例患者-年(阿达木单抗= 676例,英夫利昔单抗= 547例,依那西普= 521例),其他生物制剂组暴露时间为336例患者-年。结核病的发病率在对照组为1.01/1000患者-年,在抗肿瘤坏死因子使用者中为2.87患者-年(阿达木单抗= 4.43/1000患者-年;依那西普= 1.92/1000患者-年,英夫利昔单抗= 1.82/1000患者-年)。其他生物制剂组无结核病例发生。抗肿瘤坏死因子组的平均药物暴露时间为27(11)个月。结论使用合成DMARDs和抗肿瘤坏死因子制剂的患者结核的发病率高于使用合成DMARDs和合成DMARDs和非抗肿瘤坏死因子制剂的患者,且发生时间较晚,提示在治疗期间感染,未发现筛查失败。
{"title":"Incidence of tuberculosis among patients with rheumatoid arthritis using TNF blockers in Brazil: data from the Brazilian Registry of Biological Therapies in Rheumatic Diseases (Registro Brasileiro de Monitoração de Terapias Biológicas – BiobadaBrasil)","authors":"Claudia Leiko Yonekura , Rene Donizeti Ribeiro Oliveira , David C. Titton , Roberto Ranza , Aline Ranzolin , André L. Hayata , Ângela Duarte , Inês G. Silveira , Hellen M. da S. de Carvalho , Júlio C. Bertacini de Moraes , Mirhelen Mendes de Abreu , Valéria Valim , Washington Bianchi , Claiton Viegas Brenol , Ivanio A. Pereira , Izaias Costa , José C. Macieira , José R.S. Miranda , Luiz S. Guedes-Barbosa , Manoel B. Bertolo , Paulo Louzada-Junior","doi":"10.1016/j.rbre.2017.05.005","DOIUrl":"10.1016/j.rbre.2017.05.005","url":null,"abstract":"<div><h3>Objectives</h3><p>To assess the incidence of tuberculosis and to screen for latent tuberculosis infection among Brazilians with rheumatoid arthritis using biologics in clinical practice.</p></div><div><h3>Patients and methods</h3><p>This cohort study used data from the Brazilian Registry of Biological Therapies in Rheumatic Diseases (Registro Brasileiro de Monitoração de Terapias Biológicas – BiobadaBrasil), from 01/2009 to 05/2013, encompassing 1552 treatments, including 415 with only synthetic disease-modifying anti-rheumatic drugs, 942 synthetic DMARDs combined with anti-tumor necrosis factor (etanercept, infliximab, adalimumab) and 195 synthetic DMARDs combined with other biologics (abatacept, rituximab and tocilizumab). The occurrence of tuberculosis and the drug exposure time were assessed, and screening for tuberculosis was performed. Statistical analysis: Unpaired <em>t</em>-test and Fisher's two-tailed test; <em>p</em> <!--><<!--> <!-->0.05.</p></div><div><h3>Results</h3><p>The exposure times were 981 patient-years in the controls, 1744 patient-years in the anti-TNF group (adalimumab<!--> <!-->=<!--> <!-->676, infliximab<!--> <!-->=<!--> <!-->547 and etanercept<!--> <!-->=<!--> <!-->521 patient-years) and 336 patient-years in the other biologics group. The incidence rates of tuberculosis were 1.01/1000 patient-years in the controls and 2.87 patient-years among anti-TNF users (adalimumab<!--> <!-->=<!--> <!-->4.43/1000 patient-years; etanercept<!--> <!-->=<!--> <!-->1.92/1000 patient-years and infliximab<!--> <!-->=<!--> <!-->1.82/1000 patient-years). No cases of tuberculosis occurred in the other biologics group. The mean drug exposure time until the occurrence of tuberculosis was 27(11) months for the anti-TNF group.</p></div><div><h3>Conclusions</h3><p>The incidence of tuberculosis was higher among users of synthetic DMARDs and anti-TNF than among users of synthetic DMARDs and synthetic DMARDs and non-anti-TNF biologics and also occurred later, suggesting infection during treatment and no screening failure.</p></div>","PeriodicalId":101096,"journal":{"name":"Revista Brasileira de Reumatologia (English Edition)","volume":"57 ","pages":"Pages 477-483"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.rbre.2017.05.005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35194682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-01-01DOI: 10.1016/j.rbre.2015.07.015
Ganesh Kumar, Amieleena Chhabra, Vivek Dewan, Tribhuvan Pal Yadav
Objectives
To study the prevalence of idiopathic musculoskeletal pain (IMSP) in school going children and its impact on daily life.
Methods
One thousand eighteen apparently healthy school children aged 5–16 years were assessed and analysed for IMSP and its associated problems. Standard tests for significance were applied.
Results
One hundred and sixty-five (16.2%) children mostly males (55.2%) reported IMSP. Lower limbs (52.1%) were the most common location of pain. More than 1 year of pain history was present in 15%. Thirty-seven percent children complained of discomfort during walking, 30.9%, had pain during physical exercise, 29.2% had difficulty attending lessons and 4.2% had interference in pursuing hobbies. The children were also further sub grouped into preadolescents and adolescents. There was significant difference in pain duration and duration of each pain episode in the two groups (p = 0.01). A significant number of children (21.2%) with IMSP reported school absenteeism (p < 0.001). A significant number of adolescents had history positive for contact sports (p = 0.001). Sleep disturbances were also reported to be higher in children with IMSP (29% vs. 5.7%, p = 0.001). Other associated problems in children with IMSP found were day time tiredness (51.1%), headache (47.3%) and abdominal pain (24.8%).
Conclusions
Prevalence of IMSP in school children aged 5–16 yrs was found to be 16.2% and a significant percentage of these children experience interference with daily activities including school absenteeism.
{"title":"Idiopathic musculoskeletal pain in Indian children–Prevalence and impact on daily routine","authors":"Ganesh Kumar, Amieleena Chhabra, Vivek Dewan, Tribhuvan Pal Yadav","doi":"10.1016/j.rbre.2015.07.015","DOIUrl":"10.1016/j.rbre.2015.07.015","url":null,"abstract":"<div><h3>Objectives</h3><p>To study the prevalence of idiopathic musculoskeletal pain (IMSP) in school going children and its impact on daily life.</p></div><div><h3>Methods</h3><p>One thousand eighteen apparently healthy school children aged 5–16 years were assessed and analysed for IMSP and its associated problems. Standard tests for significance were applied.</p></div><div><h3>Results</h3><p>One hundred and sixty-five (16.2%) children mostly males (55.2%) reported IMSP. Lower limbs (52.1%) were the most common location of pain. More than 1 year of pain history was present in 15%. Thirty-seven percent children complained of discomfort during walking, 30.9%, had pain during physical exercise, 29.2% had difficulty attending lessons and 4.2% had interference in pursuing hobbies. The children were also further sub grouped into preadolescents and adolescents. There was significant difference in pain duration and duration of each pain episode in the two groups (<em>p</em> <!-->=<!--> <!-->0.01). A significant number of children (21.2%) with IMSP reported school absenteeism (<em>p</em> <!--><<!--> <!-->0.001). A significant number of adolescents had history positive for contact sports (<em>p</em> <!-->=<!--> <!-->0.001). Sleep disturbances were also reported to be higher in children with IMSP (29% vs. 5.7%, <em>p</em> <!-->=<!--> <!-->0.001). Other associated problems in children with IMSP found were day time tiredness (51.1%), headache (47.3%) and abdominal pain (24.8%).</p></div><div><h3>Conclusions</h3><p>Prevalence of IMSP in school children aged 5–16 yrs was found to be 16.2% and a significant percentage of these children experience interference with daily activities including school absenteeism.</p></div>","PeriodicalId":101096,"journal":{"name":"Revista Brasileira de Reumatologia (English Edition)","volume":"57 1","pages":"Pages 8-14"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.rbre.2015.07.015","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"55048190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-01-01DOI: 10.1016/j.rbre.2017.07.002
Roberto E. Heymann , Eduardo S. Paiva , José Eduardo Martinez , Milton Helfenstein Jr. , Marcelo C. Rezende , Jose Roberto Provenza , Aline Ranzolin , Marcos Renato de Assis , Daniel P. Feldman , Luiz Severiano Ribeiro , Eduardo J.R. Souza
Objective
To establish guidelines based on scientific evidence for the diagnosis of fibromyalgia.
Material and methods
Evidence collection was performed based on 9 questions regarding the diagnosis of fibromyalgia, structured using the Patient, Intervention or Indicator, Comparison and Outcome (P.I.C.O.), with searches in the main, primary databases of scientific information. After defining the potential studies to support the recommendations, they were graded according to evidence and degree of recommendation.
{"title":"New guidelines for the diagnosis of fibromyalgia","authors":"Roberto E. Heymann , Eduardo S. Paiva , José Eduardo Martinez , Milton Helfenstein Jr. , Marcelo C. Rezende , Jose Roberto Provenza , Aline Ranzolin , Marcos Renato de Assis , Daniel P. Feldman , Luiz Severiano Ribeiro , Eduardo J.R. Souza","doi":"10.1016/j.rbre.2017.07.002","DOIUrl":"10.1016/j.rbre.2017.07.002","url":null,"abstract":"<div><h3>Objective</h3><p>To establish guidelines based on scientific evidence for the diagnosis of fibromyalgia.</p></div><div><h3>Material and methods</h3><p>Evidence collection was performed based on 9 questions regarding the diagnosis of fibromyalgia, structured using the Patient, Intervention or Indicator, Comparison and Outcome (P.I.C.O.), with searches in the main, primary databases of scientific information. After defining the potential studies to support the recommendations, they were graded according to evidence and degree of recommendation.</p></div>","PeriodicalId":101096,"journal":{"name":"Revista Brasileira de Reumatologia (English Edition)","volume":"57 ","pages":"Pages 467-476"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.rbre.2017.07.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35260101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-01-01DOI: 10.1016/j.rbre.2017.06.004
Claudia Diniz Lopes Marques , Angela Luzia Branco Pinto Duarte , Aline Ranzolin , Andrea Tavares Dantas , Nara Gualberto Cavalcanti , Rafaela Silva Guimarães Gonçalves , Laurindo Ferreira da Rocha Junior , Lilian David de Azevedo Valadares , Ana Karla Guedes de Melo , Eutilia Andrade Medeiros Freire , Roberto Teixeira , Francisco Alves Bezerra Neto , Marta Maria das Chagas Medeiros , Jozélio Freire de Carvalho , Mario Sergio F. Santos , Regina Adalva de L. Couto Océa , Roger A. Levy , Carlos Augusto Ferreira de Andrade , Geraldo da Rocha Castelar Pinheiro , Mirhelen Mendes Abreu , Georges Christopoulos
Chikungunya fever has become an important public health problem in countries where epidemics occur because half of the cases progress to chronic, persistent and debilitating arthritis. Literature data on specific therapies at the various phases of arthropathy caused by chikungunya virus (CHIKV) infection are limited, lacking quality randomized trials assessing the efficacies of different therapies. There are a few studies on the treatment of musculoskeletal manifestations of chikungunya fever, but these studies have important methodological limitations. The data currently available preclude conclusions favorable or contrary to specific therapies, or an adequate comparison between the different drugs used.
The objective of this study was to develop recommendations for the treatment of chikungunya fever in Brazil. A literature review was performed via evidence-based selection of articles in the databases Medline, SciELO, PubMed and Embase and conference proceedings abstracts, in addition to expert opinions to support decision-making in defining recommendations. The Delphi method was used to define the degrees of agreement in 2 face-to-face meetings and several online voting rounds. This study is part 2 of the Recommendations of the Brazilian Society of Rheumatology (Sociedade Brasileira de Reumatologia – SBR) for the Diagnosis and Treatment of chikungunya fever and specifically addresses treatment.
基孔肯雅热在发生流行病的国家已成为一个重要的公共卫生问题,因为半数病例发展为慢性、持续性和使人衰弱的关节炎。关于基孔肯雅病毒(CHIKV)感染引起的关节病不同阶段特异性治疗的文献资料有限,缺乏评估不同治疗效果的高质量随机试验。有一些关于治疗基孔肯雅热肌肉骨骼表现的研究,但这些研究在方法学上有重要的局限性。目前可获得的数据排除了支持或反对特定治疗的结论,或不同药物之间的充分比较。这项研究的目的是为巴西基孔肯雅热的治疗提出建议。文献综述是通过基于证据的选择Medline、SciELO、PubMed和Embase数据库中的文章和会议论文集摘要,以及专家意见来支持确定建议的决策。采用德尔菲法确定了2次面对面会议和几轮在线投票的一致程度。这项研究是巴西风湿病学会(Sociedade Brasileira de Reumatologia - SBR)关于基孔肯雅热诊断和治疗建议的第二部分,具体涉及治疗。
{"title":"Recommendations of the Brazilian Society of Rheumatology for the diagnosis and treatment of chikungunya fever. Part 2 – Treatment","authors":"Claudia Diniz Lopes Marques , Angela Luzia Branco Pinto Duarte , Aline Ranzolin , Andrea Tavares Dantas , Nara Gualberto Cavalcanti , Rafaela Silva Guimarães Gonçalves , Laurindo Ferreira da Rocha Junior , Lilian David de Azevedo Valadares , Ana Karla Guedes de Melo , Eutilia Andrade Medeiros Freire , Roberto Teixeira , Francisco Alves Bezerra Neto , Marta Maria das Chagas Medeiros , Jozélio Freire de Carvalho , Mario Sergio F. Santos , Regina Adalva de L. Couto Océa , Roger A. Levy , Carlos Augusto Ferreira de Andrade , Geraldo da Rocha Castelar Pinheiro , Mirhelen Mendes Abreu , Georges Christopoulos","doi":"10.1016/j.rbre.2017.06.004","DOIUrl":"10.1016/j.rbre.2017.06.004","url":null,"abstract":"<div><p>Chikungunya fever has become an important public health problem in countries where epidemics occur because half of the cases progress to chronic, persistent and debilitating arthritis. Literature data on specific therapies at the various phases of arthropathy caused by chikungunya virus (CHIKV) infection are limited, lacking quality randomized trials assessing the efficacies of different therapies. There are a few studies on the treatment of musculoskeletal manifestations of chikungunya fever, but these studies have important methodological limitations. The data currently available preclude conclusions favorable or contrary to specific therapies, or an adequate comparison between the different drugs used.</p><p>The objective of this study was to develop recommendations for the treatment of chikungunya fever in Brazil. A literature review was performed <em>via</em> evidence-based selection of articles in the databases Medline, SciELO, PubMed and Embase and conference proceedings abstracts, in addition to expert opinions to support decision-making in defining recommendations. The Delphi method was used to define the degrees of agreement in 2 face-to-face meetings and several online voting rounds. This study is part 2 of the Recommendations of the Brazilian Society of Rheumatology (Sociedade Brasileira de Reumatologia – SBR) for the Diagnosis and Treatment of chikungunya fever and specifically addresses treatment.</p></div>","PeriodicalId":101096,"journal":{"name":"Revista Brasileira de Reumatologia (English Edition)","volume":"57 ","pages":"Pages 438-451"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.rbre.2017.06.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35195217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}